Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2016

View Archived Issues

Dnmt3a haploinsufficiency transforms Flt3-ITD myeloproliferative disease

Nelfinavir as salvage strategy for targeted melanoma therapy

Taltz now available for the treatment of plaque psoriasis in U.S.

Positive topline results presented from the first phase III trial of tofacitinib in PsA

Halaven receives positive CHMP opinion on new indication in Europe

Millennium Pharmaceuticals begins phase I trial of TAK-931 in Japan

Highland Therapeutics presents positive pivotal trial results for Benjorna in ADHD

Ironwood Pharmaceuticals to discontinue development of IW-9179 for gastroparesis

First patient treated in phase III combination study evaluating avelumab and Inlyta in RCC

Epizyme develops PRMT inhibitors

Shire patents dopamine transporter inhibitors

Bristol-Myers Squibb patent describes free fatty acid receptor agonists

High-affinity Fab XOMA-129 shows promise in hypoglycemia models

NantBioScience enters CRADA with NCI

Shire's phase III study of SHP-465 in ADHD meets primary endpoint

FDA approves infliximab biosimilar Inflectra in the U.S.

Baxalta's immune globulin with recombinant human hyaluronidase named FDA orphan drug for CIDP

Oxidative stress regulators predict hepatocellular carcinoma prognosis

Sysmex's Oncobeam test gets CE Mark approval

Homeobox protein identified as biomarker to detect fungal infections in the esophagus

AMU, Daiichi and Mitsubishi launch company to investigate capillary stem cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...